Author

Huilai Zhang

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

Observed institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

OpenAlex ID: A5133748422

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

2026 · John P. Leonard, Marek Trněný, et al. · Journal of Clinical Oncology · 3

Works count: 1

Citation count: 3

H-index: 1

I10-index: